Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Chan Yoon Cheah, Connie Y. Ma, Huang Huang, Antonia Kwan, Michael C. Wei, Shen Yin, Nancy L. Bartlett

Open source

DOI: 10.1200/jco.23.02329
Published: 2024-07-01
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.23.02329,
  title = {Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study},
  author = {Lihua E. Budde and Sarit Assouline and Laurie H. Sehn and Stephen J. Schuster and Sung-Soo Yoon and Dok Hyun Yoon and Matthew J. Matasar and Francesc Bosch and Won Seog Kim and Loretta J. Nastoupil and Ian W. Flinn and Mazyar Shadman and Catherine Diefenbach and Chan Yoon Cheah and Connie Y. Ma and Huang Huang and Antonia Kwan and Michael C. Wei and Shen Yin and Nancy L. Bartlett},
  year = {2024},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco.23.02329},
  url = {https://doi.org/10.1200/jco.23.02329}
}

RIS

TY  - JOUR
TI  - Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
AU  - Lihua E. Budde
AU  - Sarit Assouline
AU  - Laurie H. Sehn
AU  - Stephen J. Schuster
AU  - Sung-Soo Yoon
AU  - Dok Hyun Yoon
AU  - Matthew J. Matasar
AU  - Francesc Bosch
AU  - Won Seog Kim
AU  - Loretta J. Nastoupil
AU  - Ian W. Flinn
AU  - Mazyar Shadman
AU  - Catherine Diefenbach
AU  - Chan Yoon Cheah
AU  - Connie Y. Ma
AU  - Huang Huang
AU  - Antonia Kwan
AU  - Michael C. Wei
AU  - Shen Yin
AU  - Nancy L. Bartlett
PY  - 2024
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco.23.02329
UR  - https://doi.org/10.1200/jco.23.02329
ER  -

APA

Budde, L. E., Assouline, S., Sehn, L. H., Schuster, S. J., Yoon, S., Yoon, D. H., Matasar, M. J., Bosch, F., Kim, W. S., Nastoupil, L. J., Flinn, I. W., Shadman, M., Diefenbach, C., Cheah, C. Y., Ma, C. Y., Huang, H., Kwan, A., Wei, M. C., Yin, S., & Bartlett, N. L. (2024). Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02329

Source records

crossref · retrieved 2026-09-26T19:11:50.992Z